Compare Stocks: QNCX, OKUR, TLSA, and COYA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.98 -2.0%	$4.65	$3.71 ▼ $7.75	$119.17M	0.61	139,655 shs	120,194 shs
OKUR OnKure Therapeutics	$2.76 -4.8%	$3.67	$2.23 ▼ $5.38	$117.15M	0.23	142,954 shs	442,229 shs
QNCX Quince Therapeutics	$29.00 -6.5%	$28.85	$15.10 ▼ $909.98	$31.53M	1.31	18,949 shs	40,769 shs
TLSA Tiziana Life Sciences	$0.98 -2.9%	$1.00	$0.76 ▼ $2.33	$128.53M	0.52	611,348 shs	389,012 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	0.00%	+3.89%	+10.68%	-16.31%	-7.47%
OKUR OnKure Therapeutics	0.00%	-1.69%	-23.48%	-35.56%	+15.54%
QNCX Quince Therapeutics	0.00%	+5.16%	-8.15%	+68.37%	-90.37%
TLSA Tiziana Life Sciences	0.00%	+11.53%	0.00%	-17.89%	-50.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.98 -2.0%	$4.65	$3.71 ▼ $7.75	$119.17M	0.61	139,655 shs	120,194 shs
OKUR OnKure Therapeutics	$2.76 -4.8%	$3.67	$2.23 ▼ $5.38	$117.15M	0.23	142,954 shs	442,229 shs
QNCX Quince Therapeutics	$29.00 -6.5%	$28.85	$15.10 ▼ $909.98	$31.53M	1.31	18,949 shs	40,769 shs
TLSA Tiziana Life Sciences	$0.98 -2.9%	$1.00	$0.76 ▼ $2.33	$128.53M	0.52	611,348 shs	389,012 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	0.00%	+3.89%	+10.68%	-16.31%	-7.47%
OKUR OnKure Therapeutics	0.00%	-1.69%	-23.48%	-35.56%	+15.54%
QNCX Quince Therapeutics	0.00%	+5.16%	-8.15%	+68.37%	-90.37%
TLSA Tiziana Life Sciences	0.00%	+11.53%	0.00%	-17.89%	-50.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	207.90% Upside
OKUR OnKure Therapeutics	2.25	Hold	$17.50	534.06% Upside
QNCX Quince Therapeutics	2.62	Moderate Buy	$206.71	612.81% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNCX, OKUR, TLSA, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/22/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
9/22/2026	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$77.00
9/22/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/21/2026	OKUR OnKure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/26/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$7.95M	14.70	N/A	N/A	$2.06 per share	2.42
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
OKUR OnKure Therapeutics	-$59.52M	-$3.50	N/A	N/A	N/A	N/A	-49.01%	-45.77%	11/5/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest QNCX, OKUR, TLSA, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million
8/4/2026	Q2 2026	OKUR OnKure Therapeutics	-$0.5350	-$0.31	+$0.2250	-$0.31	$0.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	13.40	13.40
OKUR OnKure Therapeutics	N/A	26.75	26.75
QNCX Quince Therapeutics	N/A	14.52	14.52
TLSA Tiziana Life Sciences	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
OKUR OnKure Therapeutics	90.98%
QNCX Quince Therapeutics	30.75%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	6.10%
OKUR OnKure Therapeutics	2.17%
QNCX Quince Therapeutics	5.60%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
OKUR OnKure Therapeutics	45	40.40 million	39.52 million	N/A
QNCX Quince Therapeutics	38	1.02 million	960,000	Optionable
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable

QNCX, OKUR, TLSA, and COYA Headlines

Recent News About These Companies

Tiziana Begins Phase 2a BANYAN Trial Of Intranasal Foralumab In ALS Patients

2 hours ago | rttnews.com

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

September 28 at 9:32 AM | proactiveinvestors.com

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

September 28 at 8:16 AM | markets.businessinsider.com

Tiziana Life Sciences Completes Last Patient Last Visit in Phase 2A Inform-Ms Trial of Intranasal Foralumab

September 22, 2026 | marketscreener.comM

BTIG Research Reaffirms "Buy" Rating for Tiziana Life Sciences (NASDAQ:TLSA)

September 22, 2026 | marketbeat.com

Tiziana Doses Final Patient In Phase 2a INFORM-MS For Foralumab; Topline Data In Oct '26

September 21, 2026 | rttnews.com

Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October

September 21, 2026 | finance.yahoo.com

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

September 21, 2026 | markets.businessinsider.com

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

September 21, 2026 | proactiveinvestors.com

Tiziana Life Sciences Ltd(NasdaqCM:TLSA) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Why is Tiziana Life Sciences stock gaining Thursday?

September 17, 2026 | msn.com

Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up

September 17, 2026 | rttnews.com

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

September 17, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

September 17, 2026 | markets.businessinsider.com

Tiziana Life Sciences consensus price target decreased by 11.11% to $8.16

September 15, 2026 | msn.com

Tiziana Life Sciences (TLSA) Expected to Post Quarterly Earnings on Friday

September 11, 2026 | marketbeat.com

BTIG initiates coverage of Tiziana Life Sciences (TLSA) with buy rating

September 3, 2026 | msn.com

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

September 3, 2026 | proactiveinvestors.com

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

August 24, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

August 24, 2026 | globenewswire.com

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Acquires $81,292.79 in Stock

August 7, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, OKUR, TLSA, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

$4.98 -0.10 (-1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$5.08 +0.10 (+2.01%)

As of 07:30 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

OnKure Therapeutics NASDAQ:OKUR

$2.76 -0.14 (-4.83%)

Closing price 04:00 PM Eastern

Extended Trading

$2.76 0.00 (-0.18%)

As of 07:30 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Quince Therapeutics NASDAQ:QNCX

$29.00 -2.00 (-6.45%)

Closing price 04:00 PM Eastern

Extended Trading

$29.04 +0.04 (+0.14%)

As of 07:30 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Tiziana Life Sciences NASDAQ:TLSA

$0.98 -0.03 (-2.92%)

Closing price 04:00 PM Eastern

Extended Trading

$1.05 +0.07 (+6.99%)

As of 07:40 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, OKUR, TLSA, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, OKUR, TLSA, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, OKUR, TLSA, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, OKUR, TLSA, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

OnKure Therapeutics NASDAQ:OKUR

Quince Therapeutics NASDAQ:QNCX

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, OKUR, TLSA, and COYA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, OKUR, TLSA, and COYA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, OKUR, TLSA, and COYA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, OKUR, TLSA, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

OnKure Therapeutics NASDAQ:OKUR

Quince Therapeutics NASDAQ:QNCX

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools